Lindus Health, the anti-CRO transforming how clinical trials are run, has been awarded funding by ARIA to develop a groundbreaking AI system for trial design. In collaboration with Professor Nobuko Yoshida’s team at the University of Oxford, the project will pioneer methods for AI that can offer mathematically provable safety guarantees — a first for clinical trial planning.
The initiative is part of ARIA’s Safeguarded AI program, led by David “davidad” Dalrymple, which aims to bring the rigour of aviation and nuclear safety to AI in healthcare. Nijat Hasanli, Lindus Health’s Head of Product, said the work will “eliminate risks and transform the way we develop medical interventions.”
